This CME-accredited activity, Multiple Myeloma - Hematologic Malignancies, is designed to improve the care of myeloma patients by educating clinicians involved in cancer care. This activity is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with a comprehensive overview of current and emerging strategies for the management of multiple myeloma. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care of myeloma.
Course Accreditations
This activity is supported with an Independent Medical Education Grant from: Novartis 2 AMA PRA Category 1 Credits™ The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission. 2 Nursing Contact Hours Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours. 2 ABIM MOC II Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Course Summary
| Events Starts | Events Ends |
|---|---|
| 3/12/2025 | 3/12/2025 |
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Pathologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
Target Audience
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: